Treatment Of OUD

Medication-Assisted Treatment

Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies, which is effective in the treatment of opioid use disorders (OUD) and can help some people to sustain recovery. Common

Brigham and Women’s Hospital team of experts, under the direction of Dr. Joji Suzuki offers comprehensive assessments and treatment recommendations for opioid use withdrawal and detoxification for patients on all points of the spectrum with OUD.

Brigham and Women’s Faulkner Hospital offers comprehensive program with clinical services for individuals with OUD and other substance use disorders. Led by Dr. Claudia Rodriguez, in addition to the use of common MAT’s such as Buprenorphine and Naltrexone, Brigham Faulkner also offers a range of therapy options.

Psychosocial Support

Psychosocial support addresses both psychological and social needs of individuals, families and communities. Brigham’s Addiction Psychiatry Division provides OUD patients with support by offering community through tools such as 12 step meetings, seeking out familial support (based on the patients preference) and offering a sober social network. Patients are also educated on addiction and recovery and are taught relapse prevention skills. This model also addresses any psychiatric co-morbidities.

Co-Occurring Disorders

Understanding the interactions between mental health and addiction along with addictions and other co-morbidities is something the Brigham Health Division of Psychiatry is dedicated to. With programs already in place such as the Brigham Health Bridge Clinic and the Brigham Infectious disease department APR works diligently to create and discover innovative solutions to treat all aspect of each OUD patients needs.

Personalized Medicine

Acute Pain
Chronic Pain
Opioid Dependency
Genetic Testing

Innovative Data Resources

Machine Learning
Artificial Intelligence
Acute Indicators for OUD
Data resources beyond BWH

Brigham Health a global leader in opioid and pain innovation